PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis – Global Drug Forecast and Market Analysis to 2022:Life Sciences Market Research Reports

Life Sciences Market Research Reports

Got an anatomy exam soon? Use the most efficient tool to learn anatomy and be prepared for your next exam like no one else. Make your anatomy learning experience an unforgettable one. From our sponsors

PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis – Global Drug Forecast and Market Analysis to 2022 Oct 18th 2013, 00:00, by swapnil The lupus therapeutics market is dominated by generics and GlaxoSmithKline's Benlysta is the only drug that has gained marketing approval for SLE in more than 50 years. Following Benlysta's launch, patients' uptake has remained low, but due to its associated high price-tag Benlysta has managed to grow the lupus market in terms of value and is currently the second top-selling drug in this market, having generated approximately $107m in 2012 in the seven major markets. The top-selling drug in lupus in terms of value is Roche's off-label Rituxan, which GlobalData estimates generated approximately $170m in 2012 in the seven major … Order / Buy a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=120530. Complete report details with Table of Contents and more @ http://www.rnrmarketresearch.com/pharmapoint-systemic-lupus-erythematosus-and-lupus-nephritis-global-drug-forecast-and-market-analysis-to-2022-market-report.html.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions